-
Mashup Score: 0VJOncology – The video journal of oncology - 3 day(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Novel advances in PD-1 refractory melanoma - 3 day(s) ago
Adnan Khattak, MBBS, FRACP, Royal Perth Hospital, Perth, Australia, explores the emerging treatment strategies for PD-1 refractory melanoma, including neoadjuvant therapy. Preoperative immune checkpoint inhibitors have been a promising treatment avenue, where their efficacy can be assessed early. Patients who have a robust complete response tend to have better outcomes. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 15Post-ASCO 2024 Highlights - 4 day(s) ago
Webinar series by VJOncology from 19–24 June 2024 featuring presentations & discussions on selected abstracts from ASCO 2024
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0VJOncology – The video journal of oncology - 5 day(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0VJOncology – The video journal of oncology - 6 day(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7
Mariana Brandao, MD, PhD, from the Institute Jules Bordet in Brussels, Belgium, discusses the challenges in timely assessment and access to care for patients with stage III lung cancer. She highlights the low percentage of patients receiving PET-CT scans within the required timeframe and the disparities in access to brain MRI and pathological nodal staging. Dr Brandao emphasizes the importance of functional operability assessments, including exercise testing and rehabilitation, in improving surgical outcomes. This interview took place at the BTOG 2024 congress in Belfast, UK. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Gerard Walls, MB MRCP MSc FRCR, Queens University in Belfast, UK, discusses the NI-HEART analysis aimed at addressing the challenges of collecting cardiac toxicity events after curative intent radiotherapy in lung cancer. Leveraging Northern Ireland’s integrated electronic healthcare system, the study successfully captured health events post-radiotherapy. Dr Walls highlights the importance of addressing unknowns regarding cardiotoxicity in lung cancer radiotherapy, utilizing expertise from Belfast and connections across the UK and Ireland. This interview took place at the BTOG 2024 congress in Belfast, UK. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6
Adam Januszewski, St Bartholomew’s Hospital in London, provides an overview of a session he chaired at the BTOG 2024 congress focusing on therapeutics, particularly exploring newer classes of drugs like antibody drug conjugates (ASCs) and bispecific T cell engagers (BiTEs). With Prof. Egbert Smit and Prof. Fiona Blackwell as speakers, discussions delved into the potential use of these agents in patients with lung cancer. The session covered trials using teratoma in small cell lung cancer (SCLC), emphasizing promising response rates and the need for further investigation amid challenges regarding side effects. Additionally, Prof. Egbert Schmidt highlighted the role of ADCs, particularly addressing patient selection criteria and the efficacy of targeting mutations like HER2. This interview took place at the BTOG 2024 congress in Belfast, UK. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserve
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0VJOncology – The video journal of oncology - 10 day(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0SECOMBIT: treatment sequencing in metastatic melanoma and incidence of brain metastasis - 10 day(s) ago
Georgina V. Long, PhD, MBBS, FRACP, FAHMS, The University of Sydney, North Sydney, Australia, discusses the Phase II SECOMBIT (NCT02631447) trial, which evaluated the best sequential approach for combo immunotherapy (I-O; ipilimumab plus nivolumab) and combo target therapy (T-T; encorafenib plus binimetinib) in patients with metastatic melanoma. Patients either received T-T until progression and then I-O (arm A), received I-O until progression and then T-T (arm B), or were treated with a ‘sandwich’ strategy (T-T, I-O, T-T; arm C). In a follow-up analysis, incidence of and timing to brain metastasis onset was investigated. Patients in arms B and C had a lower risk of developing brain metastasis compared to patients in arm A. Additionally, patients with high tumor mutational burden (TMB) had improved brain metastasis-free survival. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain. These works are owned by Magdalen Medical Publis
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
📢1 week until all things GI cancer are debated virtually at #GDUGI2023! Keep an eye on https://t.co/ys1d8pDAKO for all the updates…💻 @GreatDebatesCME #GDUGI2023 #CRCSM #PancSM #ESOCSM #STCSM #HPBCSM https://t.co/Bj1V9ui2l2